Kronos Bio, Inc. (NASDAQ:KRON) major shareholder Fund V. L.P. Omega bought 450,000 shares of the stock in a transaction dated Wednesday, October 14th. The shares were acquired at an average price of $19.00 per share, with a total value of $8,550,000.00. Following the completion of the acquisition, the insider now directly owns 2,437,662 shares of the company’s stock, valued at approximately $46,315,578. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Kronos Bio stock opened at $32.06 on Friday. Kronos Bio, Inc. has a twelve month low of $25.50 and a twelve month high of $34.90.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients.

See Also: Google Finance Portfolio Tips and Tricks

Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with's FREE daily email newsletter.